BiotechTube
FocalOne

FocalOne

Paris, France· Est.
focalone.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Focal One is a commercial-stage medical device company focused on revolutionizing prostate cancer therapy through its robotic focal HIFU platform. Its flagship Focal One® system offers a non-invasive, non-surgical, and non-radiation alternative for targeted prostate tissue ablation, positioned between active surveillance and radical therapies. The company is actively building its commercial footprint, supported by clinical evidence and partnerships with leading medical institutions, targeting a significant gap in the prostate cancer management continuum.

UrologyOncology

Technology Platform

Integrated robotic system combining High-Intensity Focused Ultrasound (HIFU) for tissue ablation with real-time ultrasound imaging, robotic positioning for sub-millimetric accuracy, and software for MRI/ultrasound fusion (HIFUsion®) for precise treatment planning.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The growing demand for minimally invasive treatments that preserve quality of life in prostate cancer creates a large addressable market.
The clinical gap between active surveillance and radical therapy represents a significant unmet need that focal HIFU is uniquely positioned to fill.
Partnerships with leading cancer institutes provide validation and can accelerate adoption through reference sites.

Risk Factors

Long-term oncologic efficacy data for focal HIFU is still maturing, which may slow adoption among conservative urologists.
The competitive landscape includes other focal therapy modalities and HIFU systems.
Securing comprehensive insurance reimbursement is critical for widespread patient access and hospital purchasing decisions.

Competitive Landscape

Focal One competes in the focal therapy for prostate cancer market against other energy-based ablation technologies, including cryotherapy (e.g., Galil Medical/Boston Scientific), laser ablation, and irreversible electroporation (e.g., AngioDynamics' Nanoknife). It also competes with other HIFU system providers, such as EDAP TMS with its Ablatherm and Focal One systems (historically a point of legal contention), and Sonacare Medical. Competition is based on technology precision, clinical data, workflow integration, and commercial partnerships.

More companies in Oncology (General) →More companies in France →